This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

GLP-1 medications for weight loss are all the rage, but they come with some side effects. Here are my top 10 supplements I take everyday while on Zepbound.

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Specifically, CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited.